☆ 4.6 Review

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

FRONTIERS IN MICROBIOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Review Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review

Imran Sulemankhil et al.

Summary: With the widespread administration of Pfizer-BioNTech, Moderna, and Janssen vaccines, the incidence of severe COVID-19 infection has significantly decreased. However, there have been reports of serious side effects associated with these vaccines. This article describes a case of myocarditis following the administration of the Janssen vaccine in a healthy, young male and reviews the available literature on COVID-19 vaccine-related myocarditis and its possible pathogenesis. Despite the potential risk of myocarditis, the benefits of the vaccines outweigh the risks.

CARDIOVASCULAR REVASCULARIZATION MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin et al.

Summary: The Ad5-nCoV vaccine showed a 57.5% efficacy against PCR-confirmed COVID-19 infection at least 28 days post-vaccination and demonstrated safety in healthy adults aged 18 years and older during the phase 3 trial.

LANCET (2022)

添加到收藏夹

Article Medicine, General & Internal

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

J. Sadoff et al.

Summary: The Ad26.COV2.S vaccine was found to be 52.9% effective against moderate to severe-critical Covid-19 after a single dose, with protection lasting for at least 6 months. Efficacy varied depending on the Covid-19 variant, but higher protection was observed against severe cases, medical intervention, and death compared to other outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cell Biology

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Simone Lanini et al.

Summary: Safe and effective COVID-19 vaccines are crucial for ending the pandemic. A vaccine called GRAd-COV2, based on a gorilla adenovirus and expressing the spike protein of SARS-CoV-2, has been evaluated for safety and immunogenicity in healthy younger and older adults.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults

Jin Young Ahn et al.

Summary: We assessed the safety and immunogenicity of two recombinant DNA vaccines, GX-19 and GX-19N, for COVID-19. Both vaccines were found to be safe and well tolerated. GX-19N induced humoral and broad SARS-CoV-2-specific T-cell responses, but had lower neutralizing antibody responses, indicating a need for further improvement in immunogenicity.

LANCET MICROBE (2022)

添加到收藏夹

Article Virology

Adverse Events following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Nonhealthcare Workers

Ahlam A. Alghamdi et al.

Summary: This study aimed to investigate the side effects of the first dose of AstraZeneca COVID-19 vaccine among healthcare workers and non-healthcare workers. The results showed that the reported side effects were common but not severe in both groups. Healthcare workers experienced more symptoms and had a longer duration of symptoms compared to non-healthcare workers.

INTERVIROLOGY (2022)

添加到收藏夹

Review Medical Laboratory Technology

An overview on inactivated and live-attenuated SARS-CoV-2 vaccines

Saeed Khoshnood et al.

Summary: This study provides a review of inactivated SARS-CoV-2 vaccines that are undergoing phase 3 and 4 clinical trials, including the trial participants, vaccine producers, efficacy, adverse effects, vaccine components, and other vaccine features.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2022)

添加到收藏夹

Article Medicine, General & Internal

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade et al.

LANCET (2022)

添加到收藏夹

Review Virology

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Vivek P. Chavda et al.

Summary: This paper discusses the potential of replicating viral vectors as vaccine carriers for SARS-CoV-2. Despite being the third member of human coronaviruses, SARS-CoV-2 has a much wider range of transmission compared to previous coronaviruses. Although there is a possibility of zoonotic origin, no animal originated coronavirus similar to the initial edition of SARS-CoV-2 has been identified so far.

VIRUSES-BASEL (2022)

添加到收藏夹

Article

The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review

Tafere M. Belete

Open Microbiology Journal (2022)

添加到收藏夹

Review Microbiology

A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19

Mohsen Heidary et al.

Summary: Efforts to develop a safe and efficient vaccine for COVID-19 are ongoing globally. Currently, there are 161 vaccine candidates in different clinical phases worldwide, as reported by the World Health Organization.

FRONTIERS IN MICROBIOLOGY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2

Javier T. Granados-Riveron et al.

Summary: The review highlights the rapid development of mRNA-based COVID-19 vaccines within less than a year after the first SARS-CoV-2 infection. These vaccines elicit broadly protective immune responses and are amenable to rapid and flexible manufacturing processes, aiding in an agile response to the current pandemic.

BIOMEDICINE & PHARMACOTHERAPY (2021)

添加到收藏夹

Review Virology

Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review

Nidhi Chauhan et al.

Summary: The emergence of SARS-CoV-2 in 2020 led to the urgent need for COVID-19 vaccines, prompting global efforts in understanding the pathogenicity of the virus. Scientists worldwide quickly worked on developing vaccines, drawing from previous knowledge on SARS and MERS-related coronaviruses. Collaboration and financial support are essential for the mass-scale development of effective COVID-19 vaccines.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Immunology

DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

Vivek P. Chavda et al.

Summary: DNA vaccines have the potential to provide protection against SARS-CoV-2 by transforming host cells into protein factories that trigger the immune system to produce antibodies. This vaccine platform offers advantages such as strong cellular immune response, high safety margin, and simple production process, making it a robust choice for large-scale production.

EXPERT REVIEW OF VACCINES (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Virology

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval

Ebenezer Tumban

Summary: SARS-CoV-2 candidate vaccines targeting the spike protein are showing promising results in phase I/II trials, with some already granted emergency use authorization. Expectations are high for phase III trials and recommendations for post-approval phase IV studies.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Infectious Diseases

Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose

Franklin Claro et al.

Summary: The study demonstrated that all individuals in Venezuela who received two doses of the Sputnik V vaccine triggered an antibody response. Seropositive individuals showed a strong antibody response against RBD after the first vaccine dose, with no significant increase after the second dose.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Allergy

Principles and Challenges in anti-COVID-19 Vaccine Development

Zuzana Strizova et al.

Summary: Despite rising cases of SARS-CoV-2 infection in European countries, prevention through vaccination is seen as the best hope for controlling the spread of the virus. Various types of vaccines, including viral vector-based, genetic, attenuated, and protein-based vaccines, are being tested in over 80 clinical trials with some reaching advanced stages.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Review Medicine, Research & Experimental

DNA vaccines against COVID-19: Perspectives and challenges

Marcelle Moura Silveira et al.

Summary: The urgent need for COVID-19 vaccines has led to a focus on DNA vaccines as a promising alternative due to their ability to elicit strong immune responses and production advantages. This review summarizes the current research and advancements of DNA vaccines against COVID-19, with a particular emphasis on progress in clinical trials.

LIFE SCIENCES (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Controversy surrounding the Sputnik V vaccine

Mario Cazzola et al.

Summary: The Sputnik V COVID-19 vaccine, a vector vaccine, shows high efficacy above 97% in real world data, with the advantages of low cost and no need for ultra-cold storage. However, there are important shortcomings such as potential reduction in immunogenicity, decrease in antibody titres with age, and reduced neutralizing capacity against certain virus variants.

RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran

Farhang Babamahmoodi et al.

Summary: The Sputnik V COVID-19 vaccine developed by the Gamalia institute has a high rate of side effects in Iran, with more common occurrences in females and younger individuals. However, the vaccine is able to produce high levels of antibodies, supporting the manufacturer's reports on its immunogenicity against COVID-19.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Immunology

An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages

Hamid Motamedi et al.

Summary: The development of COVID-19 candidate vaccines involves various types, including inactivated vaccines, subunit vaccines, DNA/RNA vaccines, etc. Currently, dozens of vaccines are in clinical trials or pre-clinical stages. In addition to the novel coronavirus vaccines, BCG and plant-derived vaccines are also being studied for their potential role in controlling COVID-19.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Immunology

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database

Mansour Tobaiqy et al.

Summary: Thrombotic adverse events, particularly with the Oxford-AstraZeneca vaccine, were rare but associated with fatal outcomes. Pulmonary embolism was significantly associated with a fatal outcome, with higher rates reported for Pfizer and Oxford-AstraZeneca vaccines.

VACCINES (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Stefania Capone et al.

Summary: The study introduced a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike protein of SARS-CoV-2, which showed high immunogenicity in mice and macaques. The research highlighted the superiority of the pre-fusion stabilized Spike antigen in inducing ACE2-interfering, SARS-CoV-2-neutralizing antibodies. Selection of the vector backbone and preliminary data identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting its translation into a phase I clinical trial.

MOLECULAR THERAPY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Immunology

Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience

Yotam Levin et al.

VACCINE (2021)

添加到收藏夹

Article Immunology

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Susanne Rauch et al.

Summary: mRNA technologies have shown clinical efficacy against COVID-19, with the CVnCoV vaccine demonstrating strong immune responses and protection against SARS-CoV-2 in preclinical studies. Overall, CVnCoV represents a potent and safe candidate for a COVID-19 vaccine.

NPJ VACCINES (2021)

添加到收藏夹

Review Immunology

Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ali Pormohammad et al.

Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.

VACCINES (2021)

添加到收藏夹

Article Immunology

The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland

Piotr Rzymski et al.

Summary: The study demonstrates varying levels of trust in COVID-19 vaccines across producers, with mRNA vaccines being received with high acceptance. It emphasizes the need for effective and continuous science communication when fighting the pandemic.

VACCINES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic

Sarah P. Otto et al.

Summary: After a year into the COVID-19 pandemic, attention has shifted to the emergence and spread of variants of concern (VOCs) of SARS-CoV-2. These variants have shown detrimental effects on virus transmission and severity, prompting global efforts to understand their impact on disease control and public health interventions. Efforts are being made to explore the evolutionary processes involved in the emergence of new variants and to minimize their impact on the ongoing pandemic.

CURRENT BIOLOGY (2021)

添加到收藏夹

Review Immunology

COVID-19 vaccines

Duduzile Ndwandwe et al.

Summary: The COVID-19 pandemic has led to significant advancements in vaccine development, with billions of doses administered worldwide by mid-2021. However, it is crucial to ensure equal access and optimal uptake of vaccines in all countries in order to bring an end to the pandemic.

CURRENT OPINION IN IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu et al.

Summary: The study evaluated the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine in adults without COVID-19 from China. It found that the aerosol vaccine was well tolerated, and two doses elicited neutralising antibody responses similar to one dose of intramuscular injection. An aerosolised booster vaccination at 28 days after the first intramuscular injection induced strong IgG and neutralising antibody responses. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Coronapod: CureVac disappoints in COVID vaccine trial

Noah Baker et al.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Hiam Chemaitelly et al.

Summary: A study showed that the mRNA-1273 vaccine is highly effective against the B.1.1.7 and B.1.351 variants of concern, with efficacy rates of 100% and 96.4% respectively. The vaccine's effectiveness increases rapidly in the weeks following the first dose, reaching maximum efficacy after the second dose, providing strong protection against severe COVID-19 outcomes.

NATURE MEDICINE (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Namit Chaudhary et al.

Summary: mRNA vaccines have been established as a rapid, effective, and safe approach for protecting individuals from infectious diseases, especially during the COVID-19 pandemic. Further research is needed to optimize mRNA vaccine design, delivery, and applications for a range of infectious diseases.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G Kremsner et al.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Donata Hoffmann et al.

Summary: The study demonstrates that two spike encoding mRNA vaccines provide effective protection against the variants of concern B.1.351 and the ancestral strain BavPat1 of SARS-CoV-2, despite lower neutralizing antibody titers against B.1.351.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Letter Biotechnology & Applied Microbiology

Can children of the Sputnik V vaccine recipients become symptomatic?

Esmaeil Mehraeen et al.

Summary: This study observed that 83% of the children of Sputnik V recipients developed symptoms such as fever and chills, possibly related to Adenovirus infection. Larger studies are needed to validate these results.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Cell Biology

Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization

Qiqi Cao et al.

Summary: COVID-19, caused by SARS-CoV-2, is a severe global health threat, with vaccines being highly effective in combating it. By using scRNA/V(D)J-seq technology to study peripheral blood mononuclear cells from COVID-19 vaccine trial participants longitudinally, enhanced immune responses were observed, providing insights for assessing vaccine efficacy.

CELL DISCOVERY (2021)

添加到收藏夹

Article Immunology

IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population

Oscar Guzman-Martinez et al.

Summary: The study found that the BNT162b2 vaccine produced S1 IgG antibodies in 80.3% of participants after the first dose, increasing to 98.36% after the second dose. The Ad5-nCoV vaccine generated S1 IgG antibodies in 88.89% of vaccinated individuals. Both vaccines were deemed safe, with women generally producing more antibodies after vaccination.

VACCINES (2021)

添加到收藏夹

Article Immunology

Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

Jorge Hernandez-Bello et al.

Summary: The study found that the ability of the Ad5-nCoV vaccine to induce antibody production depends on whether the recipient has a history of prior COVID-19 infection, and anti-Ad5 antibodies also increase after 21 days post-vaccination. It is recommended to administer a booster dose of the Ad5-nCoV vaccine to individuals without a history of COVID-19 infection.

VACCINES (2021)

添加到收藏夹

Article Health Care Sciences & Services

Antibody Response Following a Two-Dose mRNA Vaccination Regimen, in Health Care Workers of a Tertiary Hospital in Athens, Greece

Elissavet Kontou et al.

Summary: The analysis revealed that women, younger age groups, previously infected individuals, and those working in COVID-19 clinics exhibited a greater increase in antibodies after receiving the BNT162b2 mRNA COVID-19 vaccine. Individuals with prior COVID-19 infection or working in COVID-19 clinics displayed significantly higher antibody titers following the first dose of the vaccine.

JOURNAL OF PERSONALIZED MEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

mRNA vaccines for COVID-19: what, why and how

Jung Woo Park et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant impact on human lives, with mRNA vaccines emerging as promising candidates due to their rapid development time, cost-effectiveness, versatility in design, and proven ability to induce immune response.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance

Marco Montalti et al.

Summary: A study conducted in San Marino on Sputnik V vaccine recipients showed that it is well tolerated in individuals aged 60 years and above, with an AEFI incidence of around 76% for two-dose recipients.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Cell Biology

Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose

Andres H. Rossi et al.

Summary: The study evaluated the antibody responses of healthcare workers in Argentina after receiving the Sputnik V vaccine, showing that previously infected individuals had higher levels of antibodies and virus-neutralizing capacity after receiving a single dose of the vaccine.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Review Infectious Diseases

COVID-19 vaccines: Frequently asked questions and updated answers

M. Lefebvre et al.

Summary: This text discusses the development, mode of action, effectiveness, limitations, and usage of COVID-19 vaccines, highlighting the importance of vaccines in ending the pandemic, and includes recommendations from the French health authorities as of February 14, 2021.

INFECTIOUS DISEASES NOW (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas et al.

Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current advances in the development of SARS-CoV-2 vaccines

Annoor Awadasseid et al.

Summary: COVID-19 caused by SARS-CoV-2 has become a global pandemic, with China being at the forefront of vaccine development. The last inactivated vaccine international clinical trial has been launched in the UAE, showing promising progress in creating efficacious and safe vaccines against SARS-CoV-2.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity of a DNA vaccine candidate for COVID-19

Trevor R. F. Smith et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Review Chemistry, Multidisciplinary

Current Status of COVID-19 (Pre)Clinical Vaccine Development

Tingting Ye et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Thermostable mRNA Vaccine against COVID-19

Na-Na Zhang et al.

CELL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic

Colin D. Funk et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

Andrew Clark et al.

LANCET GLOBAL HEALTH (2020)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Gregory A. Poland et al.

LANCET (2020)

添加到收藏夹

Review Multidisciplinary Sciences

SARS-CoV-2 vaccines in development

Florian Krammer

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

A review of COVID-19 vaccines in development: 6 months into the pandemic

Merlin Sanicas et al.

PAN AFRICAN MEDICAL JOURNAL (2020)

添加到收藏夹

Review Toxicology

COVID-19: Therapeutics and Their Toxicities

Michael A. Chary et al.

JOURNAL OF MEDICAL TOXICOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

Sergio E. Rodriguez et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Immunology

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Margaret A. Liu

VACCINES (2019)

添加到收藏夹

Article Immunology

Study of serum bactericidal and splenic activity of Total-OMP-CagA combination from Brucella abortus and Helicobacter pylori in BALB/c mouse model

Amir Hossein Abadi et al.

MICROBIAL PATHOGENESIS (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

Ellen Suder et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)

添加到收藏夹

Review Immunology

Developments in Viral Vector-Based Vaccines

Takehiro Ura et al.

VACCINES (2014)

添加到收藏夹

Review Immunology

HIV and co-infections

Christina C. Chang et al.

IMMUNOLOGICAL REVIEWS (2013)

添加到收藏夹

Article Immunology

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

E DeJesus et al.

CLINICAL INFECTIOUS DISEASES (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.